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Abstract
Duchenne muscular dystrophy (DMD) represents one of the most devastating types of muscular dystrophies which affect boys 
already at early childhood. Despite the fact that the primary cause of the disease, namely the lack of functional dystrophin 
is known already for more than 30 years, DMD still remains an incurable disease. Thus, an enormous effort has been made 
during recent years to reveal novel mechanisms that could provide therapeutic targets for DMD, especially because gluco-
corticoids treatment acts mostly symptomatic and exerts many side effects, whereas the effectiveness of genetic approaches 
aiming at the restoration of functional dystrophin is under the constant debate. Taking into account that dystrophin expres-
sion is not restricted to muscle cells, but is present also in, e.g., endothelial cells, alterations in angiogenesis process have 
been proposed to have a significant impact on DMD progression. Indeed, already before the discovery of dystrophin, several 
abnormalities in blood vessels structure and function have been revealed, suggesting that targeting angiogenesis could be 
beneficial in DMD. In this review, we will summarize current knowledge about the angiogenesis status both in animal mod-
els of DMD as well as in DMD patients, focusing on different organs as well as age- and sex-dependent effects. Moreover, 
we will critically discuss some approaches such as modulation of vascular endothelial growth factor or nitric oxide related 
pathways, to enhance angiogenesis and attenuate the dystrophic phenotype. Additionally, we will suggest the potential role 
of other mediators, such as heme oxygenase-1 or statins in those processes.
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Duchenne muscular dystrophy and other 
dystrophies
Duchenne muscular dystrophy (DMD, MIM #310200) is one 
of the most severe forms of inherited muscular dystrophies. 
It is a devastating X-linked genetic disorder that affects 
approximately 1 in 5000–6000 boys [1] and is caused by 
the mutation in the dystrophin gene (DMD, MIM #300377), 
the largest gene in the human genome, located on the chro-
mosome Xp21 [2]. Several syndromes associated with pro-
gressive skeletal muscle wasting and degeneration diseases 
(known as dystrophinopathies) are described, with Becker 
muscular dystrophy (BMD) and limb-girdle muscular dys-
trophies (LGMD) being the more frequently diagnosed 
after DMD [3]. The DMD gene contains 79 exons, encodes 
a 14-kb mRNA and produces the protein product with a 
molecular weight of 427 kDa [4, 5]. The most common 
forms of the mutations leading to DMD are the intragenic 
deletions and duplications (they account for over two-thirds 
of the mutations) with point mutations detected in 20–30% 
of patients [4]. In-frame mutations causing the truncation of 
the protein result rather in the much milder disease, BMD 
[6].
Dystrophin is a crucial component of the dystrophin-asso-
ciated protein complex, responsible for the connection of 
the sarcolemma and extracellular matrix (ECM) to the actin 
cytoskeleton within skeletal myofibers and cardiomyocytes 
[7]. The postulated role of dystrophin is to protect the sarco-
lemma from the stress of repeated contractions by providing 
an indirect link between the subsarcolemmal actin and the 
intermediate filaments in the muscle fiber with ECM com-
ponents. Therefore, mutations in the dystrophin gene result-
ing in the lack of functional dystrophin cause mechanical 
instability and myofibers destruction with repeated cycles of 
necrosis and regeneration as well as inflammatory response. 
Degenerating myofibers accumulate immunoglobulins IgA 
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and IgG [8] and release creatine kinase (CK) as well as 
lactate dehydrogenase (LDH) that can be detected in the 
plasma as markers of muscle damage [9, 10]. Neutrophils 
and pro-inflammatory macrophages invade dystrophic mus-
cles to remove debris and by secretion of Th1 cytokines, 
they regulate the activation, proliferation, migration, and dif-
ferentiation of satellite cells (SCs), muscle stem cells. Pro-
inflammatory cytokines and membrane instability lead to 
self-sustaining activation of the innate immune response—
induction of MHC I and II on muscle cells, recruitment of 
Th and Tc lymphocytes and constant damage of muscles. 
From the other hand, Treg cells try to compensate the pro-
inflammatory effects as they secrete immunosuppressive 
IL-10 and reduce expression of IFNγ released by Th lym-
phocytes [11, 12]. In dystrophic muscles, continuous cycles 
of damage and inflammation over years lead to the replace-
ment of muscles by fibrous connective tissues and fat, and 
as a consequence, improper and final loss of muscle function 
[11, 13].
Still, new processes and molecular pathways are identi-
fied to play an important role in the modulation of DMD 
progression. The increased oxidative stress may affect both 
autophagy and mitochondrial respiration. In fact, impair-
ment in the autophagy process, leading to the accumulation 
of damaged organelles, was reported in muscles from DMD 
patients [14]. Moreover, the mitochondrial dysfunction in 
dystrophic skeletal muscle is well documented and it not 
only contributes to the reductions in resting ATP content but 
also leads to the impairment of autophagy, apoptosis, inflam-
mation, fibrosis, and satellite cells death (reviewed in [15]).
Recent studies concentrate more on the involvement of 
SCs in DMD progression. Until recently dystrophin was 
thought to be expressed only in myotubes and myofibres, but 
its presence was also confirmed in other cell types, including 
muscle stem cells [16]. In SCs, dystrophin is responsible for 
the maintenance of the appropriate cell polarity during the 
cell division. As a consequence of dystrophin deficiency, 
dysfunction of asymmetric SCs division and cell polarity 
has been observed resulting in the inefficient generation of 
myogenic progenitors and impaired muscle regeneration 
[16]. This would explain the fact that although the number 
of SCs in mdx mice is increased, their regenerative capacity 
is compromised by the alterations in SCs self-renewal and 
maintenance. Moreover, it might be suggested that observed 
defects can be translated to DMD patients as well, emphasiz-
ing that DMD pathology, except direct muscle weakening 
and fragility, should be considered as the muscle stem cell 
disease [16]. Moreover, our group has revealed some notable 
alterations in the shape of differentiating SCs isolated from 
dystrophic mice, what could potentially reflect their func-
tional impairment [10].
First symptoms of the disease start in early childhood 
with skeletal muscle weakness, including fatigue, difficulty 
in standing up (the so-called Gower’s maneuver), walking 
as well as frequent falls and a characteristic Trendelen-
burg gait. Unfortunately, the disease progresses rapidly, 
and around the age of 12, patients lose the ability to walk, 
develop spinal curvature known as kyphosis, paralysis and 
finally die due to respiratory or cardiac failure (dilated 
cardiomyopathy) around 20 years of age [17] (summarized 
in Fig. 1).
There is no cure for patients suffering from muscular dys-
trophies currently. Glucocorticoids (GCs), with prednisolone 
and deflazacort being most commonly used, still serve as a 
gold standard therapy, acting mostly as anti-inflammatory 
drugs [18]. With the use of steroids and multidisciplinary 
care, particularly the mechanical ventilation, the lifes-
pan of some affected individuals can be now extended to 
30–40 years of age. Nonetheless, except clear, long-term 
beneficial effects of GCs [19], their daily administration 
is associated with various adverse effects [20]. Although 
Quattrocelli et al. [21] showed that weekly, intermittent GCs 
administration provides a better alternative to a daily regi-
men without eliciting muscle atrophy, still pharmacologi-
cal approaches are mainly mitigating the symptoms of the 
disease, acting as non-specific agents. Thus, during recent 
years, a great amount of effort has been put into the investi-
gation of novel, gene-based therapies, such as exon skipping 
approach or suppression of stop codons.
Recently, more attention is paid to induced pluripotent 
stem cells (iPSCs) technology and their potential applica-
tion in DMD treatment. Many studies have described vari-
ous attempts to develop and characterize human iPSC-based 
models of DMD (summarized in [22]) and iPSCs differen-
tiated to cardiomyocytes to model dilated cardiomyopathy 
observed in DMD patients [23, 24]. In addition, Filareto 
et al. [25] using corrected-iPSC-derived myogenic precur-
sors (derived from mdx/utrn−/− mice fibroblasts and engi-
neered to express a micro-utrophin, Pax3 and Pax7) showed 
that they are able to engraft in vivo following local and sys-
temic transplantation and this resulted in improved muscle 
strength of mdx/utrn−/− mice.
Furthermore, with the development of CRISPR/Cas9 
technology the possibilities for the restoration of functional 
dystrophin arisen dramatically [26]. For example, Young 
et al. [27] have found that removal of exons 45–55 resulted 
in the expression of the stable dystrophin protein in both 
cardiomyocytes and skeletal myotubes in vitro. Such genetic 
manipulation caused functional effects as improved mem-
brane integrity and CK level similar to the wild-type cells 
was measured in reframed cells. Nonetheless, although an 
increasing number of studies report successful and beneficial 
effects of CRISPR/Cas9 in animal models of muscular dys-
trophy [28–30], genome editing tools are still far from being 
therapeutically available. Accordingly, there is a constant 
need for investigation of novel, molecular targets that could 
1509Targeting angiogenesis in Duchenne muscular dystrophy 
1 3
provide potential treatment options for patients suffering 
from muscular dystrophies.
Animal models of DMD
To better understand the basic biology behind DMD pathol-
ogy, several animal models of the disease, ranging from 
non-mammalians such as Caenorhabditis elegans [31] and 
zebrafish [32], through the mouse and canine models have 
been created, and the list is still growing. As the majority of 
models were already thoroughly described in many review 
papers [33–35], we will only briefly present some of the 
most commonly used ones in order to illustrate the complex-
ity of the subject.
Mouse model—mdx mice
Commonly used are mice with the spontaneous, nonsense, 
point mutation in 23 exon of the dystrophin gene, the so-
called mdx (C57BL/10ScSn genetic background) mice 
[35–37], with over 3000 publications on Pubmed to date. 
Similar to the DMD, mdx mice lack functional dystrophin 
protein what first suggested that this model might be the 
equivalent of the human disease in mice [38]. Moreover, 
typical histological features such as muscle degeneration, 
a variation of the fiber size and occurrence of centrally 
nucleated, regenerating fibers can be observed in these 
mice [36]. However, the timeline and intensity of the 
symptoms differ between mdx animals and DMD patients. 
In humans, muscle degeneration is progressive through the 
whole life of the patients, with muscle tissue being contin-
uously replaced by fibro-fatty connective tissue (reviewed 
in [38]). In the mdx model, first onsets of the disease occur 
around 2–3 weeks after birth but then, the disease slows 
down when mice are around 3-month-old. The amount of 
fibrotic replacement is also significantly lower and regen-
erative capacity seems to be much more potent [36]. Fur-
thermore, in comparison to DMD patients, the lifespan of 
the mdx mice is not as significantly shortened, probably 
due to the much slower disease progression as many of 
the more serious symptoms occur later than in DMD [39]. 
Importantly, the first signs of cardiomyopathy (measured 
by echocardiography) appear around 10 months of age, 
whereas histological examination revealed interstitial car-
diac fibrosis in 17-month-old mice [40]. Nevertheless, mdx 
Fig. 1  The pathology of Duchenne muscular dystrophy (DMD). The 
progression of DMD proceeds rapidly due to the several direct and 
indirect effects. First symptoms of the disease start in early child-
hood, around the age of 2–3, with skeletal muscles degeneration and 
weakness being the primary cause of dystrophin deficiency. Con-
comitantly, repeated cycles of necrosis and regeneration of muscle 
fibers trigger a strong immune response. As the consequence, patients 
lose the ability to walk around the age of 12 and finally, around the 
age of 20, they die due to the cardiac or respiratory dysfunction. As 
no complete cure for DMD patients exists currently, investigation of 
new processes and molecular pathways that could play an important 
role in DMD is still needed. Accordingly, mitochondrial dysfunc-
tion, as well as impairment in autophagy and possibly angiogenesis 
processes, was also suggested to contribute to the progression of the 
disease
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mice still serve as the most frequently used animal model 
of DMD.
Mouse model—mdx/utrn−/− mice
Quite frequently used model relies on additional utrophin 
deficiency. Utrophin is a large, cytoskeletal protein which is 
very similar to dystrophin. In healthy muscle fibers, utrophin 
in strongly expressed only during the developmental stage 
and is further being replaced by the dystrophin [41, 42]. 
In adults, its appearance is limited to the vascular smooth 
muscles, nerves, endothelium, and neuromuscular junctions 
[41, 42]. Interestingly, utrophin was shown to be upregu-
lated and constantly accumulated in regenerating muscle 
fibers of mdx mice [43]. Its occurrence might suggest some 
compensatory mechanism for the lack of dystrophin protein, 
especially because utrophin expression is normally down-
regulated after the birth (reviewed in [44]).
Indeed, mdx mice additionally lacking utrophin have a 
more severe disease phenotype with progressive weight loss, 
muscle weakening and ultimately, they die prematurely at 
20 weeks of age due to respiratory failure [45, 46]. Of note, 
whereas mdx single knockout mice do not exhibit signs 
of cardiomyopathy until 10 months of age [40], in mdx/
utrn−/− mice first symptoms of heart dysfunction, such as 
cardiomyocyte necrosis, appear at 8–10 weeks of age [46] 
and by 15 weeks of age decreased left ventricular fractional 
shortening and ejection fraction, as well as cardiac fibrosis, 
was observed [47].
Mouse model—mdx/mTR−/−
Another interesting and very useful murine model is con-
nected to the differences in the length of telomeres. As 
shown by many studies, despite their shorter lifespan, mice 
have much longer telomeres when compared to humans 
[48]. To see what will be the result of telomerase shorten-
ing in mdx mice, the special strain has been created. mdx/
mTR−/− mice possess a deletion in the RNA component 
TERC (mTR) of telomerase and they show more severe dys-
trophic phenotype than mdx mice which in many aspects 
resembles what is happening in DMD patients [49]. Sacco 
et  al. [49] observed impaired self-renewal capacity of 
SCs, accumulation of fibrotic tissue, increased CK levels, 
dilated cardiomyopathy and also shortened lifespan (around 
12 months) of mdx/mTR−/− mice in comparison to mdx/
mTR+/− and wild-type mice. Importantly, defects in mus-
cle regenerative response due to progressive exhaustion, 
impaired proliferation and engraftment potential of SCs 
necessary to fuel myofiber repair is a major consequence of 
telomerase shortening (reviewed in: [35]).
However, mdx/mTR−/− and similarly mdx/utrn−/− mice 
are not as frequently used as mdx animals, mostly because 
of the additional mutation, which makes them a much more 
complex genetic model than mdx mice.
Canine model—golden retriever muscular 
dystrophy (GRMD)
Golden retriever muscular dystrophy (GRMD) is one of the 
best characterized DMD models to date. The advantage of 
GRMD over mdx mice is that the phenotype of the disease 
is much more similar to the human DMD. Relatively early 
age of the disease onset (visible even in 10-day-old dogs) 
and also increased the speed of symptoms progression in 
such animals have been observed [50, 51]. Notably, while 
the GRMD model seems to be more clinically relevant than 
the mdx mice, its usage is limited by the high costs of the 
experiment and the number of dogs that would be needed.
Despite the great deal of light that was shed on the subject 
of DMD pathology, there is still a need for the refinement, as 
none of known so far models exhibit the full range of human 
DMD symptoms while being good genetic equivalents.
The role of angiogenesis in DMD—general 
overview
Several abnormalities have been suggested to affect DMD 
progression and additionally, the dysfunctional angiogenesis 
was also proposed to have an impact on DMD pathology. 
Angiogenesis, a process of new blood vessel formation from 
preexisting ones undeniably plays a pivotal role in muscles 
which comprise nearly 40% of the human body mass. Thus, 
the efficient delivery of oxygen as well as the transport of 
various metabolites is required for proper functioning of 
the muscles and thereby the whole body (reviewed in [52]). 
As mentioned earlier, dystrophin is expressed not only in 
muscle cells but is present also in SCs, vascular smooth 
muscle cells and endothelial cells [16, 53, 54] suggesting 
that in DMD patients the formation of blood vessels and the 
properties of endothelial cells might be impaired (Fig. 2). 
Indeed, already before the discovery of dystrophin by Kun-
kel et al. [2, 55], several studies aimed at the investigation 
of potential defects in vasculature which could be respon-
sible for DMD pathology. As it was initially suspected, the 
presence of grouped necrosis in muscles of DMD patients 
could be explained by impaired capillary blood supply 
and ischemia [56, 57]. Although the vascular theory was 
extensively discussed, some studies undermined its valid-
ity, as no direct evidence for severe abnormalities in blood 
vessel morphology as well as in blood flow were observed 
[58–62]. Nonetheless, notable alterations, such as swollen 
and pale endothelial cells were revealed and their impaired 
function which could at least contribute to the pathogenesis 
of DMD was suggested [58, 62–64]. Moreover, Miike et al. 
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[64] demonstrated aberrations in blood vessel structure in 
muscle biopsy specimens from DMD patients. Both the cap-
illaries and endothelial cells area were much greater in DMD 
patients with almost completely occluded, narrow lumen in 
comparison to control subjects. Replication of the basement 
membrane around the vessels, as well as the presence of 
degenerating and regenerating capillaries, were also evident 
[64]. Such observations were further confirmed by the same 
group in Fukuyama-type congenital muscular dystrophy 
(FCMD) [65]. More recent studies focused on the analysis 
of vasculature in muscle tissues of mdx mice. Whole-mount 
imaging of tibialis anterior (TA) muscle, as well as immu-
nostaining of arterioles in gracilis muscle, revealed marked 
decrease in the vasculature of mdx mice in comparison to 
wild-type animals [66, 67]. Additionally, altered biomechan-
ical properties of carotid arteries in mdx and sarcoglycan-δ 
 (sgcd−/−, a model of LGMD dystrophy) mice were also 
noticed [68]. All of the above strongly emphasize morpho-
logical aberrations of blood vessels both in mice models of 
DMD and in DMD patients, which potentially could have 
functional consequences.
Evidence for angiogenesis alterations in animal 
models of DMD with respect to age
Interestingly, Straino et al. [69] showed the normal angio-
genic response in a model of hindlimb ischemia in mdx mice. 
Moreover, even better arteriogenesis (increased arterioles 
but not capillaries length density) was observed in com-
parison to control animals even though no changes at the 
basal conditions were revealed. Angiogenic response to 
wound healing with concomitant increase in arterioles (but 
not capillaries) density was also observed in mdx mice in 
comparison to the wild-type counterparts [69]. Some con-
tradictory effects have been described in the next studies. In 
2013, Palladino et al. [70] reported the angiogenic impair-
ment of the vascular endothelial cells isolated from mdx 
mice, including their migration, proliferation and tube for-
mation in comparison to wild-type controls. The differences 
between the above-mentioned studies may be related to the 
age of animals which were used (Fig. 3). Straino et al. [69] 
examined young (2-month-old) mdx mice, which still have a 
quite potent regenerative capacity, whereas in the latter study 
older, around 6-month-old mdx mice, have been studied [70]. 
Importantly, the comprehensive analysis of age-dependent 
alterations of skeletal muscle microvasculature was per-
formed most recently by Latroche et al. [71]. By utilizing 
specific mouse model: Flk-1GFP/+mice crossed with mdx 
mice (in which GFP is targeted in VEGFR-2 (Flk-1) gene 
locus) which enable visualization of all blood vessels and by 
applying innovative structural and non-invasive functional 
approaches such as 3D microvascular network organization 
and nuclear magnetic resonance (NMR), respectively, they 
compared muscle vasculature in young, 3-month-old versus 
old, 12-month-old dystrophic mice. In line with previous 
assumptions, although microvascular network organization 
Fig. 2  Possible alterations in 
angiogenesis process in DMD. 
Within the healthy skeletal mus-
cle, dystrophin expression is not 
only restricted to muscle cells, 
but it is also present in other 
cell types including smooth 
muscle cells (SMCs), satellite 
cells (SCs) and endothelial 
cells (ECs). In DMD, the lack 
of dystrophin is associated 
with altered morphology and 
properties of ECs what poten-
tially could lead to alterations 
in blood vessel structure and 
function
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in young dystrophic mice was not changed (except a slight 
decrease in terminal arteriole density), an increase both in 
muscle perfusion and mitochondrial oxidative phosphoryla-
tion was noticed. Oppositely, old mice displayed significant 
vasculature alteration with a concomitant reduction in mus-
cle perfusion [71]. Additionally, age-related differences in 
muscle vasculature were also noticed in GRMD dogs. No 
differences in microvessel density, as well as total vascular 
area, were found in young, 1- to 3-month-old dystrophic 
dogs in comparison to control ones. Conversely, in older, 4- 
to 10-month-old dogs, microvessel depletion was observed; 
however, only in sartorius cranialis muscle [72].
It was further suggested that satellite cells, which are 
pivotal for regeneration process, can be, at least partially, 
responsible for impaired angiogenesis in aged mice, espe-
cially because they lie close to the capillaries and except 
their direct involvement in the myogenesis, they may also 
strongly influence angiogenic response, e.g., by secreting 
pro-angiogenic vascular endothelial growth factor (VEGF) 
[73]. Moreover, the close proximity of SCs to capillaries 
and thus the crosstalk between SCs and endothelial cells 
(mostly via Notch signaling) influences SCs self-renewal 
and quiescence [74]. Indeed, Rhoads et al. [75] have shown 
that SCs isolated from aged, 12-month-old mdx male mice 
exhibit reduced capacity to promote angiogenesis in vitro. 
The number, as well as the length of the sprouts in three-
dimensional microvascular fragment model exposed to 
conditioned media (CM) from dystrophic mice, were sig-
nificantly decreased as compared to the effect observed 
with CM from wild-type animals. Furthermore, the level of 
VEGF, as well as hypoxia-inducible factor-1α (HIF-1α) in 
dystrophic SCs, was significantly decreased in comparison 
to control cells, emphasizing their potential contribution to 
impaired angiogenesis process in dystrophic mice [75]. Res-
toration of VEGF expression was then proposed as a novel 
strategy to improve angiogenesis in DMD and the efforts 
made in this area will be discussed in more details below.
The role of VEGF in DMD—pro‑angiogenic 
and pro‑myogenic effect of VEGF
It was suggested that one of the strategies to improve the 
dystrophic phenotype is to regulate the deficient angiogen-
esis in mdx mice. VEGF, a potent pro-angiogenic molecule, 
stimulating the migration, proliferation, and survival of 
Fig. 3  Age-related differences in angiogenesis process in dystrophic 
mice. Alterations in the angiogenesis process in muscular dystrophy 
are visible in different organs. In the brain of mdx mice, pathologi-
cal angiogenesis with, among others, increased vascular permeability 
and abnormalities in cerebral perfusion were reported. On the other 
hand, in skeletal muscles, observed effects appear to be strongly age-
dependent. In young, 2–3-month-old animals either no alterations 
or enhanced angiogenesis were documented; however, when older, 
6–12-month-old mice were analysed, impairment in the angiogenesis 
process was evident. It was further suggested that such differences 
observed in old animals might be, at least partially, explained by the 
reduced capacity of satellite cells (SCs) to promote angiogenesis pro-
cess
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endothelial cells is acting mostly through VEGFR-2 path-
way [76]. Described as the endothelial-specific growth fac-
tor, VEGF was then found to be beneficial for many other 
cell types, including neurons and muscle cells [77, 78]. 
Importantly, it exerts direct myogenic effects and was dem-
onstrated to have anti-apoptotic properties towards myogenic 
cells and was able to enhance muscle force restoration sub-
sequent to traumatic injury [78, 79]. Moreover, muscle-spe-
cific deletion of VEGF was shown not only to dramatically 
decrease capillary density but also to reduce exercise endur-
ance in mice [80, 81]. Concomitantly, it is known that VEGF 
mRNA level increases upon physical activity [82], which 
is greatly attenuated in DMD patients. Diminished level of 
VEGF associated with reduced angiogenesis and impaired 
growth of regenerated muscle fibers was also evident in mdx/
MMP-2−/− mice [83]. Hence, taking into account beneficial 
properties of VEGF related to both angiogenesis process as 
well as its involvement in myogenesis, it might be suspected 
that potential deficiency of VEGF in muscular dystrophy 
might contribute to the severe manifestation of the disease.
The level of VEGF in DMD patients and in murine 
models of DMD
Evaluation of DMD patients’ and mdx mice blood revealed 
changes in VEGF level; however, the results coming from 
those studies are rather inconclusive. Saito et al. [84] found 
an elevated level of VEGF in the serum of patients suffering 
not only from DMD but also other, much milder dystro-
phies, such as BMD. However, in this study, male dystrophic 
patients were compared to much older control subjects of 
both sexes. In contrast to DMD patients, decreased level of 
VEGF was noticed in gastrocnemius (GM) [71] and soleus 
[85] muscles of mdx mice as well as in the diaphragm of 
mdx/utrn−/− animals [86]. Moreover, transcriptome-based 
analysis of GM performed by our group revealed markedly 
diminished level of VEGF in mdx mice in comparison to 
wild-type animals (unpublished data). Interestingly, we and 
others showed that the level of microRNA-206 (miR-206), 
one of the key regulators of myogenesis (reviewed in [87]) 
is strongly upregulated in mdx mice of different ages in 
comparison to wild-type counterparts both in muscles and 
SCs [10, 88]. Except its direct and essential role in muscle 
development, miR-206 was also proposed to negatively regu-
late angiogenesis by repressing VEGF expression [89–92]. 
Notably, Bulaklak et al. [93] showed that AAV-mediated 
miR-206 inhibition not only improved overall motor function 
and attenuated dystrophic phenotype of mdx mice but was 
also associated with increased VEGF expression and con-
comitantly, induced angiogenesis activity in muscles. Alto-
gether, impaired angiogenesis with a concomitantly dimin-
ished level of VEGF strongly suggests that VEGF restoration 
could potentially exert beneficial effects on DMD pathology.
Different approaches to enhance muscle 
angiogenesis with regard to VEGF or VEGF‑related 
pathways
Several tools can be applied to achieve VEGF overexpres-
sion (Fig. 4) (reviewed in: [94, 95], but adeno-associated 
viruses (AAV), especially serotype 9 (AAV9) are mostly 
used for muscle gene transfer and efficient transduction of 
skeletal and cardiac muscle after systemic administration 
[96]. In fact, Messina et al. [97] using AAV for intramuscu-
lar VEGF delivery to mdx mice were able to show increased 
regenerating fibers area with enhanced capillary density and 
reduced area of necrotic fibers. In another study, overexpres-
sion of VEGF (again using AAVs) in dystrophic mice led to 
decrease in serum CK level and what is more important, the 
measurement of grip strength showed the functional effect 
of VEGF therapy [98]. Although muscle regeneration was 
not changed after VEGF delivery, the area of inflammation 
and necrosis was significantly reduced when compared with 
saline-treated mdx mice. Despite the fact that these experi-
ments clearly indicate the beneficial effect of VEGF overex-
pression, it has to be noted that control mice were injected 
with saline (not with control AAV vector) [98]. Importantly, 
concomitant, intravenous injection of VEGF and recombi-
nant AAV6 vector harboring microdystrophin cassette sig-
nificantly enhanced muscle-specific transduction efficiency 
in mdx mice, and thus, enabled widespread expression of 
functional microdystrophin at lower vector doses [99].
A different strategy to restore VEGF expression was 
demonstrated by Deasy et al. [100], who studied the effect 
of in vivo transplantation of muscle-derived stem cells 
(MDSCs) engineered to overexpress human VEGF. Local 
delivery of such cells into the GM of dystrophic and severe 
combined immunodeficient (mdx/SCID) mice resulted in 
marked increase in angiogenesis in comparison to mice 
injected with MDSCs control cells, as evidenced by immu-
nostaining of microvasculature marker, platelet endothelial 
cell adhesion molecule 1 (CD31). However, it has to be 
emphasized that CD31 is also expressed by immune cells, 
which are abundant in dystrophic muscles. Furthermore, 
observed changes were accompanied by enhanced muscle 
regeneration and decreased fibrosis. Conversely, the oppo-
site effects were reported when MDSCs expressing soluble 
forms-like tyrosine kinase 1 (sFlt-1, sVEGFR-1), a member 
of the VEGFR family and a negative regulator of angio-
genesis with greater affinity to bind and sequester VEGF 
than VEGFR-2 [101], were transplanted [100]. Thus, one 
could suspect that inhibition of VEGFR-1/Flt-1 (or its solu-
ble form) could result in improved angiogenesis, providing 
an alternative approach to VEGF overexpression. Indeed, 
Verma et al. [102] have reported that mdx mice develop-
mentally haploinsufficient for Flt-1 (mdx:Flt-1+/−) exhibit 
overall improvement of dystrophic phenotype with increased 
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muscle vasculature, decreased fibrosis and calcification in 
comparison to wild-type mice. Of importance, functional 
assays revealed increased muscle blood flow measured by 
the laser Doppler flow as well as ameliorated muscle con-
tractile function in mdx:Flt-1+/− mice as compared to control 
mice [102]. Although the results from this work are very 
promising, studies utilizing, e.g., small molecule inhibitors 
or antibodies specifically targeting Flt-1 should be used to 
fully address the question if inhibition of Flt-1 in postnatal 
life would be as beneficial as developmental lack of Flt-1 
(summarized in Fig. 4).
A critical view on the potential use of VEGF alone 
as a treatment option for DMD
It appears that utilization of VEGF as a potential treatment 
option for DMD patients has to be carefully considered, 
especially taking into account the dosage of VEGF being 
used, as its over-administration might exert severe adverse 
effects, ranging from edema or hemangioma formation 
[103, 104] to the development of endothelial cell-derived 
vascular tumors [105]. Additionally, due to the fact that sys-
temic VEGF clearance proceeds rapidly [106], it might be 
hypothesized that beneficial effects of VEGF will be rather 
short-lived, and thus, frequent delivery of VEGF would be 
needed to sustain VEGF-induced changes both with regard 
to angiogenesis and myogenesis processes.
Furthermore, although several studies conducted in 
murine models of DMD pointed out advantageous effects 
of VEGF on the dystrophic phenotype, one cannot forget 
that mdx mice do not develop characteristic features of the 
disease to the same extent and as early as in humans [39]. 
Gutpell et al. [107] have investigated the effect of VEGF 
administration on fibrosis markers using heterozygous mdx/
utrn+/− mice lacking dystrophin and partially utrophin. Inter-
estingly, the pro-fibrotic response of skeletal muscle fibro-
blasts isolated from 10-week-old mdx/utrn+/− mice to VEGF 
administration, with increased Acta2 expression encoding 
alpha-smooth muscle actin and enhanced stress-fiber for-
mation, in comparison to untreated control fibroblasts was 
detected [108]. Moreover, also Gutpell et al. [86] in another 
study have shown that although expression of VEGF is 
Fig. 4  Angiogenic-dependent possibilities to improve dystrophic phe-
notype. Several angiogenic-dependent approaches to improve dys-
trophic phenotype were suggested. Among them, vascular endothelial 
growth factor-A (VEGF) overexpression obtained by several methods 
including adeno-associated adenoviral vectors (AAVs) harbouring 
VEGF, muscle-derived stem cells (MDSCs) engineered to overex-
press VEGF or direct, intramuscular delivery of growth factor have 
been tested. Nonetheless, due to the fact that VEGF overexpression 
may exert undesired effects, angiopoietin 1 (ANG1) overexpression 
alone or combined delivery of VEGF and ANG1 was proposed to 
be more beneficial than administration of VEGF alone. Moreover, 
also inhibition of vascular growth factor receptor 1 (VEGFR-1) or 
its soluble form (sVEGFR-1), a negative regulators of angiogenesis, 
is considered to have a beneficial effect in DMD. VEGFR-2 vascular 
endothelial growth factor receptor-2. Tie2 tyrosine kinase with immu-
noglobulin-like and EGF-like domains 1. *Experimentally tested, 
**requires further validation as beneficial effects were reported only 
in mice haploinsufficient for VEGFR-1
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significantly decreased in the diaphragm (but not in GM) of 
mdx/utrn+/− mice, intramuscular, short-term delivery of low 
dose VEGF does not improve blood flow, as evidenced by 
applying dynamic contrast-enhanced computed tomography 
(DCE-CT). Hence, they undermined functional, pro-angio-
genic effects of VEGF delivery and blunted an enthusiasm 
in the field of the potential use of VEGF alone as a treatment 
option for DMD. Instead, they revealed that the administra-
tion of another growth factor, angiopoietin 1 (ANG1) alone 
or in combination with VEGF significantly increased func-
tional parameters of perfusion, such as blood volume. Addi-
tionally, VEGF treatment resulted in higher collagen depo-
sition in comparison to ANG1-treated mdx/utrn+/− animals 
and ANG1 induced vessel maturation in mdx/utrn+/− hind 
limb muscle as compared to both sham-injected animals and 
VEGF-treated mice [86]. Thus, ANG1 might be another can-
didate for vascular-based therapy for DMD patients. Accord-
ingly, combination delivery of VEGF with other factors, 
such as ANG1 or insulin-growth factor-1 (IGF-1) which was 
shown to promote muscle regeneration [109], rather than 
VEGF alone, should be considered (Fig. 4).
The potential role of angiogenesis and VEGF 
in the heart muscle of murine models 
of DMD
Cardiac failure and dilated cardiomyopathy (DCM) are the 
common cause of death in patients suffering from DMD 
[110]. Although the involvement of angiogenesis process 
specifically in the heart has not been thoroughly investi-
gated, it might be suspected that dystrophin deficiency, 
similarly like in case of skeletal muscles, will also affect 
angiogenesis in cardiac tissue. Indeed, Loufrani et al. [67] 
showed lower arteriolar density in the right ventricle of 
young, 12-week-old male mdx animals in comparison to 
control mice. However, some discrepancies were reported 
in another study done by Lai et al. [111], in which no dif-
ferences in both numbers of arteries and the capillary area 
in the heart of old, female dystrophic mice were found. 
Nonetheless, except differences in age and sex of animals 
used, it has to be noted that in the latter study, mdx mice 
on C57Bl/10ScSn-Dmdmdx/J background were compared 
to the wild-type animals on C57Bl/10 background (and not 
the proper control—C57Bl/10ScSnJ), which utilization as 
controls might be questionable. Interestingly, downregula-
tion of VEGF and decreased capillary density were already 
reported in the heart of patients with end-stage DCM [112]. 
Even more significant to this discussion is the fact that dis-
turbed secretion of VEGF in the myocardium was observed 
in mdx mice exposed to hypobaric hypoxia in low-pressure 
chambers and such an effect was proposed to potentially 
promote the progression of the cardiomyopathy [113]. Of 
note, Chun et al. [114] revealed that aorta-derived mesoan-
gioblasts (ADMs) differentiated into cardiomyocytes in vitro 
and injected into the heart of young mdx/utrn−/− mice were 
able to prevent the onset of cardiomyopathy with a concom-
itant increase in the number of capillaries. Although this 
beneficial impact of ADMs transplantation on angiogenesis 
was claimed to be rather an indirect effect [115], it cannot be 
excluded that modulation of angiogenesis and VEGF expres-
sion could have a beneficial effect on DMD progression also 
with regard to the heart function.
Pathological angiogenesis in the brain 
of murine models of DMD
In addition to the well-described pathological features of 
DMD directly related to the muscle weakness, DMD affects 
also a central nervous system (CNS) leading to the men-
tal retardation in one-third of patients suffering from DMD 
[116]. Metabolic abnormalities in mdx mouse brain were 
reported in 1996 by the group of Tracey et al. [117]. Later, 
Nico et al. [118] have demonstrated for the first time that the 
microvessels area positive for VEGFR-2 as well as the area 
of neurons positive for VEGF in brain samples from 18 to 
20-month-old mdx female mice were significantly elevated 
in comparison to control ones. Increased vascularisation of 
mdx mouse brain was further confirmed by the same group 
in another study, in which increased expression of VEGFR-2 
and VEGF in younger, 5-month-old female mdx mice was 
correlated with the elevated level of HIF-1α and altered 
expression patterns of endothelial tight junction proteins 
zonula occludens-1 (ZO-1) and claudin-1 [119]. Tryptase, 
nerve growth factor (NGF), matrix metalloproteinases-2 
and-9 (MMP-2 and -9) were also suggested to be involved 
in those alterations [120, 121]. Moreover, detailed analysis 
revealed that the majority of microvessels in dystrophic mice 
were coated with abnormal endothelial cells with open tight 
junctions [122]. Blood brain barrier (BBB) breakdown and 
increased vascular permeability in the brain of mdx mice 
were observed not only in adult mice but were already vis-
ible in dystrophic embryos as well as newborn mice [123]. 
Additionally, to the results obtained by the group of Nico 
et al. [118], an elegant study performed recently by Good-
nough et al. [124] demonstrated, for the first time, functional 
abnormalities of cerebral diffusion and perfusion in male 
mdx mice at a different age. A comprehensive combina-
tion of in vitro, in vivo and ex vivo analysis of mdx brain, 
revealed disruption of BBB integrity and decreased cerebral 
diffusivity both in 2- and 10-month-old mdx mice in com-
parison to wild-type animals. Furthermore, 10-month-old 
mdx mice exhibited enhanced cerebral arteriogenesis and, 
most strikingly, diminished cerebral perfusion [124]. Such 
alterations might be related to the cerebral edema formation 
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and impaired functioning of water channels in the brain of 
mdx mice [125]. Altogether, pathological angiogenesis in the 
brain of dystrophic mice can be associated with the develop-
ment and progression of neurological dysfunction found in 
DMD patients.
Sex influences dystrophic phenotype 
and angiogenesis process
DMD affects mainly boys, but symptomatic female carriers, 
with the variable manifestation of the disease symptoms, 
are also described [126–128]. Preclinical studies on animal 
models of DMD investigate mostly male mice, but some 
were performed without respect to sex [129, 130] or were 
done solely on female mice [111, 118, 119]. Nonetheless, 
it might be envisaged that the dystrophic phenotype differs 
with respect to the sex; thereby the studies evaluating DMD 
progression in female mdx mice might not represent a reli-
able model of DMD. Indeed, a substantial number of studies 
suggest that the sex of dystrophic mice have a huge influ-
ence on the disease outcome. Shortly, it appears that young 
female mdx mice exhibit attenuated dystrophic phenotype 
in comparison to male mdx mice; however, this effect is 
strongly reversed with age [131–133].
Moreover, sex-related alterations are not only restricted 
to skeletal muscles but are also manifesting in cardiac func-
tion. Female mdx mice at 22 months of age exhibit much 
more prominent cardiac dysfunction in comparison to male 
mice, with, among others, significantly worse hemodynamic 
function and reduced ejection fraction [134]. Hence, the uti-
lization of old female mdx mice as a model to study DMD-
related cardiomyopathy was suggested [111, 135–137].
Finally, unexpected, sex-related alterations in angiogen-
esis process have been reported recently by Guéniot et al. 
[138] who studied the vascular network in 12-month-old 
female mdx mice. Complex methodology, including histo-
logical assessment as well as functional approaches, such 
as non-invasive NMR-enabled broad and reliable investiga-
tion of the angiogenesis process in female dystrophic mice. 
Strikingly, the authors showed enhanced reperfusion after 
ischemic stress followed by increased vascular density and 
elevated mitochondrial oxidative rephosphorylation capacity 
in female mdx animals in comparison to wild-type counter-
parts. Obtained results are completely opposite to the effects 
observed by the same group in age-matched male mdx mice 
[71]. The differences observed in males and females might 
be at least partially regulated by sex hormones as estragon 
and estradiol have been shown to enhance angiogenesis, 
through increased endothelial cells proliferation and migra-
tion. This effect might be mediated by the upregulation of 
endothelial nitric oxide synthase (eNOS) activity, increased 
VEGF level and adhesion molecules expression (reviewed 
in: [139]).
All of the above strongly emphasize sex-related differ-
ences in key aspects of DMD pathology, pointing out the 
possible contribution of female-specific factors, such as sex 
hormones, to those alterations [140, 141]. Altogether, sex 
has to be carefully considered when designing experimen-
tal settings utilizing dystrophic mice. It has to be pointed 
out that the effects observed in female mdx mice, also with 
respect to angiogenesis process, might not be biologically 
relevant when considering the disease which affects boys.
Other possible modulators of angiogenic 
status in DMD
As DMD is still an incurable disease, many studies concen-
trate on finding new molecular players having the capacity 
to modulate disease progression. Some selected factors are 
presented below.
Nitric oxide and DMD
As mentioned earlier, dystrophin serves as a cytoskeleton 
stabilization protein but it also may play a signaling role, 
through the localization of signaling proteins. Neuronal-
type nitric oxide synthase (nNOS) in skeletal muscle was 
demonstrated already many years ago to be a component of 
dystrophin complex [142]. nNOS synthesizes freely diffus-
ible nitric oxide (NO), a key signaling molecule regulating 
blood flow, contraction, satellite cell activation,  Ca2+ han-
dling, mitochondrial biogenesis and gene expression [143]. 
In normal, healthy muscles, NO, among other activities, may 
modulate contractile force [144], regulates exercise-induced 
glucose uptake [145] and is implicated in myofiber differ-
entiation [146]. In dystrophic muscle, the dissociation of 
nNOS from the sarcolemma and subsequent reduction in 
nNOS mRNA and protein level [147], nNOS activity [148] 
and NO production [149] may contribute to the progression 
of dystrophic phenotype (Fig. 5).
Furthermore, dystrophin regulates NO production not 
only by providing the scaffold for nNOS but also by the 
modulation of flow (shear stress)-mediated endothelium-
dependent dilation (FMD) in arteries. Loufrani et al. [67] 
reported that the lack of dystrophin induces alterations in 
flow-dependent mechanotransduction with significantly 
decreased vascular density in gracilis and cardiac mus-
cles in mdx mice in comparison to control animals. Of 
importance, these changes were attributed to significantly 
lowered NO-dependent FMD and eNOS expression [67]. 
The role of eNOS (as well as nNOS) in vascular response 
in contracting fast-twitch skeletal muscle is well known 
[150]; however, the status of eNOS in DMD has not been 
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well investigated and the results vary between different 
studies. In mdx mice, eNOS expression in skeletal mus-
cles does not seem to be changed on mRNA level [83], 
but on protein level either no changes [151, 152] or even 
elevation of eNOS was reported [153]. On the other hand, 
in a canine model of DMD, the vascular endothelial dys-
function with diminished eNOS protein level was reported 
[154]. Although the discrepancies between various studies 
are apparent, the increase in eNOS level achieved by dif-
ferent approaches was reported to exert beneficial effects 
in DMD [88, 154, 155].
NO is a potent modulator of vascular tone and muscle-
derived NO plays a role in the regulation of blood flow. This 
action relies on the modulation of vasoconstrictor response 
to activation of α-adrenergic receptors. However, this mech-
anism is defective during contraction of nNOS knockout 
mice and nNOS-deficient mdx mice [151]. What is more 
important; similar results were observed in DMD patients. 
Sander et al. [156] have found that in DMD dystrophic boys, 
expression of nNOS in muscles is greatly reduced in com-
parison to children with polymyositis (PM) or LGMD. As 
the consequence vasoconstrictor responses were not attenu-
ated in exercising forearm in children with DMD but were 
greatly decreased in those with PM or LGMD [156]. These 
data suggest that due to low production of NO by contracting 
human DMD skeletal muscles, a protective mechanism that 
blunts the α-adrenergic vasoconstrictor response to reflex 
sympathetic activation is defective and it leads to functional 
muscle ischemia when the dystrophic muscles are exercised 
[156].
Not only blood perfusion but also SCs activation and 
fusion leading to better muscle repair might be regulated by 
NO [157]. In our hands, in mdx SCs with impaired differen-
tiation potential, the downregulation of NO-related cGMP-
PKG (cGMP-dependent protein kinase) signaling pathway 
was observed. Moreover, supplementation with NO donor 
normalized the in vitro differentiation rate of SCs from mdx 
mice [10]. Moreover, NO may act as an epigenetic regulator 
in DMD—loss of nNOS can impair muscle development and 
regeneration by disrupting the normal regulation of chroma-
tin structure [158]. It was also found that NO, through modi-
fication of histone deacetylases activity (e.g. S-nitrosylation 
of HDAC2) may affect the expression of some microRNAs, 
important for muscle regeneration (reviewed in [159]). Addi-
tionally, NO released from muscles may activate MMPs, 
especially MMP-2 [160], triggering the release of some 
trophic agents, such as hepatocyte growth factor (HGF), 
known to activate satellite cells through binding to c-met 
receptor [161]. Collectively, these mechanisms are not fully 
functional in dystrophic muscles and might be responsible 
for improper muscle growth and regeneration (Fig. 5).
The possible treatment of DMD—modulation 
of NO and NO‑dependent pathways
As nNOS level is greatly reduced in DMD patients as well 
as skeletal-derived NO production is blunted, and taking 
into consideration multiple mechanisms controlled by NO, 
it was speculated that modulation of NO signaling pathway 
might serve as a possible therapy for dystrophy treatment 
Fig. 5  Impairment of NO pathway in the progression of DMD and 
therapeutic strategies to increase NOS activity and NO production. 
Neuronal-type nitric oxide synthase (nNOS) is a component of dys-
trophin complex and synthesizes freely diffusible nitric oxide (NO), 
a key signaling molecule. In dystrophic muscle, the dissociation 
of nNOS from the sarcolemma and subsequent reduction in nNOS 
level, nNOS activity, and NO production may contribute to the pro-
gression of dystrophic phenotype affecting not only blood perfusion 
but also muscle repair processes and satellite cells (SCs) properties. 
Thus, modulation of NO signaling pathway either via l-arginine and 
NO donor supplementation, genetic nNOS overexpression or 5-phos-
phodiesterase (PDE5) inhibitors was speculated to serve as a possible 
therapy for DMD. Indeed, a substantial number of studies revealed 
beneficial effects of such approaches on dystrophic phenotype, with 
decreased myofiber damage, improved vasorelaxant capacity, reduc-
tion in cardiomyopathy and anti-fibrotic effects
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(Fig. 5). Several studies have revealed a beneficial effect of 
nNOS overexpression in dystrophic mice as the reduction 
in inflammatory reaction with decreased macrophage and 
neutrophil infiltration [162] as well as anti-fibrotic effect in 
dystrophic mice was observed [163]. Reduced macrophage 
content, reduced fibrosis, and increased survival rate after 
nNOS overexpression have been demonstrated also in mdx/
utrn−/− mice [164].
In addition, l-arginine, the substrate for nNOS, has been 
proposed as a pharmacological treatment to attenuate the 
dystrophic pattern of DMD. Hnia et al. [165] reported that 
5-week-old male mdx mice treated with 200 mg/kg l-argi-
nine for 2 weeks displayed lower inflammation (decreased 
NF-κB activation and lower IL-1β, IL-6 and TNFα level) 
and stabilization of utrophin/β-dystroglycan interactions as 
well as induction of the recruitment of nNOS in the sarco-
lemma. In contrast, long-term supplementation (17 months) 
with arginine failed to protect mdx mice, as increased fibro-
sis in muscles and hearts was observed [166]. In this study, 
mdx and C57BL/6 (used as controls) mice received drinking 
water supplemented with 5 mg/ml of l- or d-arginine from 
3 weeks to 18 months of age. Intense fibrosis was observed 
after treatment with l- but not d-arginine, and only in mdx, 
not in control mice [166]. Additionally, NO donors includ-
ing diethylenetriamine (NONOate, DETA-NO) [167] or 
guaifenesin dinitrate (GDN) [168] have been shown to 
reduce disease progression and increasing muscle function 
in dystrophic mice by regulating SCs activation.
Several studies described the use of arginine butyrate, the 
compound combining two pharmacological activities which 
contribute to DMD progression—NO-pathway activation by 
arginine and HDAC inhibition by butyrate. Intraperitoneal 
administration of arginine butyrate to mdx mice resulted in 
the improvement of the dystrophic phenotype in skeletal 
muscles and diaphragm both in newborn and adult mice 
[169]. The same group has also evaluated the oral adminis-
tration of arginine butyrate and was able to demonstrate the 
improvement of cardiac function, decreased kyphosis and 
neuronal changes in treated mdx mice [170]. It should be 
also noted that Guerron et al. [171] evaluated long-term ther-
apy with arginine butyrate (treatment for 6 months, begin-
ning at 3 months of age for 5 days each week) and some 
tendency to improve grip strength and decreased fibrosis in 
the GM was observed, however, no significant changes in 
other parameters such as muscle histology, behavioral meas-
urements, heart function or serum CK levels were detected. 
However, additional experiments are needed to fully under-
stand the mechanism of this drug (proposed for the treatment 
of sickle-cell disease and β-thalassemia [172, 173]) in DMD 
patients.
Improved vasorelaxation capacity might be also sug-
gested as the therapy for DMD. NO acts mainly by the acti-
vation of soluble guanylyl cyclase (cGS) to increase the level 
of cyclic guanosine monophosphate (cGMP) and then pro-
tein kinase G is activated to induce vasodilation. Therefore, 
5-phosphodiesterase (PDE5) inhibitors, such as tadalafil and 
sildenafil, which inhibit cGMP degradation, might have a 
beneficial role in DMD treatment. Of note, the activity of 
PDE5 in mdx skeletal muscles is much higher than in control 
individuals [174, 175] but this regulation might be also age-
dependent [176]. Young mdx mice had higher cAMP and 
cGMP PDE activity in comparison to age-matched controls; 
however, the older dystrophic animals (15 weeks of age) had 
similar cGMP PDE activity and lower cAMP PDE activity 
than controls [176]. Nevertheless, many studies have shown 
the usefulness of PDE5 inhibitors in mouse models of DMD. 
Treatment with sildenafil ameliorated the age-related car-
diomyopathy [177] and reduced diaphragm weakness and 
fibrosis [178] in the mdx mice. Of note, the use of a PDE4 
inhibitor, piclamilast as well as a combination of PDE4 and 
PDE5 inhibitors also exerted beneficial, anti-fibrotic effects 
in mdx mice [179]. Finally, in DMD boys, PDE5 inhibition 
alleviated exercise-induced skeletal muscle ischemia and 
was suggested to be a putative new therapeutic strategy for 
DMD [180].
Although many studies show positive effects of NO sup-
plementation/modulation of NO signaling pathway in dys-
trophy pathology, there are also studies indicating that such 
treatment should be used with caution. Supplementation of 
dystrophic animals with sodium nitrate (85 mg/l) in drinking 
water had detrimental effects on skeletal muscle, potentially 
via  ONOO−—dependent mechanism [181].
The role of heme oxygenase‑1 in angiogenesis 
and the possible role in DMD
One of the possible therapeutic agents playing a protective 
role in DMD might be heme oxygenase-1 (HO-1, encoded 
by Hmox1 gene). This microsomal enzyme is responsible for 
the first, rate-limiting step in heme degradation pathway and 
it leads to the formation of carbon monoxide (CO), ferrous 
iron (inducing the synthesis of protective ferritin) and bili-
verdin (subsequently converted into anti-oxidant bilirubin by 
biliverdin reductase). HO-1 is a master cellular cytoprotect-
ant, not only because it deactivates deleterious properties of 
pro-oxidant heme, but mostly due to many non-canonical 
functions, including anti-apoptotic, anti-inflammatory and 
anti-oxidant properties (for review see: [182–184]). We have 
shown its crucial role as blood vessel formation regulator 
and we demonstrated that angiogenesis induced by VEGF 
[185, 186] or SDF-1 [187] depends on HO-1. We under-
lined its importance for the proper wound healing process 
[188], in tumorigenesis [183, 189–192] and in the functions 
of bone marrow-derived pro-angiogenic cells [193, 194].
Recently, we focused on the role of HO-1 in the mus-
cles (progenitor) cells biology, especially in the aspects 
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of their regeneration potential after both acute injury and 
persistent muscular degeneration. We have shown that in 
non-dystrophic mice, short-term expression of HO-1 pro-
motes myoblasts proliferation and muscle regeneration [195] 
while oppositely, its long-term expression inhibits differen-
tiation, affecting significantly muscle-specific microRNAs 
(myomirs) [196]. We have revealed a role for HO-1 in the 
progression of rhabdomyosarcoma (RMS), a soft tissue 
cancer characterized by impaired myogenic differentiation 
[197]. Interestingly, we have also reported the opposite regu-
lation between HO-1 and miR-206 in RMS cell lines and 
clinical primary tumors of the more aggressive alveolar type 
[197]. In a model of cardiotoxin-induced muscle damage, 
we have demonstrated increased muscle injury, disturbed 
proportion of M1/M2 macrophages, enhanced formation of 
arterioles and hypertrophy with the augmented rate of regen-
eration observed in injured HO-1 knockout skeletal muscle 
[198]. We have also found that HO-1-deficient satellite cells 
are prone to activation and have a higher proliferation rate 
after injury, suggesting that HO-1 is an important regulator 
of muscle repair mechanisms preventing its uncontrolled 
acceleration and hence exhaustion [198].
Our recent studies concentrated on the role of HO-1 in 
DMD progression [10]. Using mdx mice additionally lack-
ing HO-1 (mdx/HO-1−/−), as well as by applying pharmaco-
logical inhibitor of HO-1 activity in mdx mice, we observed 
increased damage and inflammation in comparison to con-
trol mice. What is important, lack of HO-1 affected also 
running capacity of dystrophic mice—mdx/HO-1−/−mice ran 
shorter distance than mdx. We also observed disturbed and 
enhanced differentiation of satellite cells isolated from mdx/
HO-1−/−mice. Finally, we have found that differentiation of 
mdx satellite cells might be normalized by supplementation 
of the cells with CO, a product of HO-1 activity as well as 
nitric oxide (NO) [10], suggested to have beneficial effects 
in DMD as discussed earlier. These data implicate HO-1 
as a possible therapeutic target to reduce the progression 
of DMD.
Statins—pleiotropic drugs regulating processes 
involved in DMD progression
Discovered 40 years ago [199], 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors, more com-
monly known as statins, are lipid-lowering drugs for the 
treatment of hypercholesterolemia and reduction of ath-
erosclerosis. Noteworthy, statins comprise many subtypes 
based on structural differences and their pharmacokinetic 
properties, including their active or lactone form, lipophilic/
hydrophilic rate, and their absorption and metabolism, what 
may affect some (slight) different effects exerted by various 
members of the family (reviewed in [200]).
Statin interaction with HMG-CoA reductase obtained 
already at nanomolar concentrations, leads to the inhi-
bition of the downstream cholesterol biosynthesis and 
numerous isoprenoid metabolites such as geranylgeranyl 
pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP). 
GGPP and FPP are key intermediates for post-translational 
modification of several cell signaling proteins, including 
the small GTPase family members Ras, Rac, and Rho. The 
isoprenylation is fundamental for the proper functioning of 
these proteins as regulators of cell shape, motility, differ-
entiation, and proliferation (reviewed in [200]), therefore 
inhibition of Ras, Rho, and Rac is suggested to be the 
major targets responsible for pleiotropic effects exerted 
by statins [201].
The anti-fibrotic role of statins is one of the most 
commonly observed in different pathological condi-
tions, including cardiac [202] and hepatic fibrosis [203]. 
Another, not connected to the lipid-lowering role is attrib-
uted to statins anti-oxidant properties. In 2012, Pignatelli 
et al. [204] showed that atorvastatin treatment in patients 
with polygenic hypercholesterolemia exerts anti-oxidant 
properties by inhibition of NADPH oxidase 2 (Nox2), 
which is one of the reactive oxygen species (ROS) gen-
erating enzyme. Moreover, in a dose-dependent man-
ner, through increased endothelial NOS (eNOS) mRNA 
stability and protein activity, statins are able to increase 
NO bioavailability [205, 206]. Augmented NO level, by 
its anti-oxidant properties might itself decrease oxida-
tive stress [207]; however, the more important role might 
be associated with regulation of angiogenesis. We have 
demonstrated that atorvastatin at a pharmacologically rel-
evant concentration (100 nM) enhanced the expression of 
eNOS in human microvascular endothelial cells (HMEC-
1). Moreover, atorvastatin prevented the hypoxia-induced 
decrease in eNOS expression [208]. The regulation of 
several angiogenic factors was observed by us after sta-
tin stimulation in HUVEC cells [209]. However, angio-
genic activity of statins seems to be cell type and dose-
dependent as shown in several (including ours) papers. 
It was demonstrated that at low, therapeutic (nanomolar) 
concentrations statins are pro-angiogenic, whereas at high 
dosage (low micromolar) we can observe the inhibition of 
angiogenic activity [209–211].
As mentioned earlier, statins inhibit Ras prenylation 
and this effect may result in downregulation of activity 
of NF-κB, which is important for many different inflam-
matory pathways [212] and is strongly activated in DMD 
[213]. In this aspect, statins were shown to downregulate 
the level of inflammatory mediators, such as monocyte 
chemoattractant protein-1 (MCP-1) and tumor necrosis 
factor alpha (TNF-α) [214].
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Statins in DMD—potential therapeutic agents?
For simplicity, DMD can be characterized by three main 
symptoms: chronic inflammation, oxidative stress, and 
fibrosis. Based on the statin pleiotropic effects that were 
described above, it seems that they could be considered as a 
good candidate to be used as therapeutic agents.
Interestingly, Whitehead et al. [215] for the first time 
described the protective effect of statins in mdx mice. The 
authors showed that simvastatin treatment at moderate daily 
dose improved muscle health, reduced inflammation, fibro-
sis, and oxidative stress. Treatment had no effect on the CK 
level, which increase is one of the markers associated with 
statin-induced myopathy. Moreover, the author decided 
to take a look at the most affected by the disease muscle, 
diaphragm, showing improvement in muscle strength and 
physiological performance. What is even more interesting, 
increase in muscle force of different muscles, reached about 
40%, what is similar to the effect obtained by the most prom-
ising so far therapies—with mini-dystrophin construct and 
exon skipping [216, 217].
Another possible mechanism of statin action was con-
nected to the regulation of autophagy, which is strongly 
impaired during DMD progression [14]. Simvastatin 
treatment was found to enhance this process in mdx mice 
and it was already shown that increased autophagy leads 
to a decrease in inflammation and fibrosis [14]. Impaired 
autophagy might be caused by CYBB/Nox2-mediated ROS 
production [218]. As mentioned before, statins decrease 
the level of Nox2, what strongly suggests that this pathway 
might contribute to intensified autophagy process [204].
DMD is a very progressive disease, starting at early age 
and the diagnosis is in many cases overdue and therapy is 
initiated when the irreversible symptoms already occurred 
[219]. Whitehead et al. [215] administrated simvastatin to 
old mdx mice and for the first time showed reversion of 
preexisting fibrosis in diaphragm muscle, suggesting that 
this drug is able to work on the already established disease. 
Based on all presented data one can claim that the therapeu-
tic application of statins should be taken into consideration; 
however, no additional studies in this area are available so 
far. On the other hand, some work underlines the unfavorable 
effects of statins.
Statins—their devastating (?) role in muscles
One of the suggested side effects of statin treatment is related 
to the induction of skeletal muscle myopathy and rhabdomy-
olysis, characterized by muscle breakdown and the release 
of intracellular content including CK and many electrolytes, 
being well-documented and most frequently described [220, 
221]. Although several mechanisms responsible for adverse 
statin-induced effects were published, this issue is a matter 
of ongoing debate.
Several in vitro studies showed toxic effects of statins. 
However, very often the concentrations used were far 
beyond the physiological range, e.g., 24 h stimulation with 
10 μM or 50 μM simvastatin, atorvastatin or rosuvastatin 
was performed in C2C12 myoblast cell line [222] or even 
100 μM cerivastatin, fluvastatin and atorvastatin was used 
to induce cell death and mitochondrial toxicity in L6 rat 
skeletal muscle cell line [223]. Importantly, however, such 
high concentrations of statins required to induce deleterious 
effects in vitro are typically greater than 1 μM. Such con-
centrations are considerably (100–1000 times) higher than 
those found in vivo in mice and humans [224]. Therefore, 
a detailed analysis of the dose of statins used in various 
experiments is needed.
There are also discrepant data about the incidence of 
different kinds of myopathy in humans after statin therapy. 
Previous studies indicated a high risk of such adverse effects, 
e.g. showing that > 10% of statin users in the general popu-
lation can be affected [225]. However, a recent systematic 
review of clinical trials found adverse muscle symptoms 
only in < 1% compared with placebo controls [225]. Statin-
related muscle symptoms also appear to be exacerbated by 
several factors, including exercise, older age and female sex 
[226, 227]. Moreover, when statin-induced rhabdomyoly-
sis cases were analyzed, it appeared, that in many patients, 
statins were used together with other drugs that could inter-
fere with statins metabolism and in some cases potentiated 
the risk of negative side effects, such as rhabdomyolysis 
[220, 221].
Nevertheless, a recent meta-analysis by Iwere and Hewitt 
clearly showed that even in aged patients (65 + years), the 
risk of statin-induced myopathy was comparable to placebo 
patients [228]. These data implicate that the fear of statin-
caused myopathy might be overestimated. Notably, the risk 
factors for statin-induced myopathy (older age, exercises, 
female sex) are not relevant to DMD boys. Nevertheless, due 
to the potential threat of muscle-related side effects, statins 
were overlooked in the past but it is probable that the work 
by Whitehead et al. [215] may start the new thinking about 
statins and muscle-related disorders (Fig. 6).
Conclusions
Although a great amount of effort has been put into the 
investigation of novel therapies, there is still no effective cure 
for DMD patients, making this pathology one of the most 
dangerous and devastating disease affecting boys already in 
early childhood. Some new players and additional mecha-
nisms contributing to DMD onset and progression have been 
identified recently. Among them, alterations in angiogenesis 
1521Targeting angiogenesis in Duchenne muscular dystrophy 
1 3
were reported both in animal models and DMD patients, 
therefore vascular-targeted therapy has been proposed as a 
treatment option for DMD to reduce ischemia and enhance 
endogenous repair processes. Nonetheless, more studies are 
warranted to fully understand the role of angiogenic media-
tors and disturbed blood vessels functioning in DMD pathol-
ogy. It can be envisaged that the dystrophin deficiency in 
endothelial cells is either responsible or at least involved 
in the angiogenesis defects observed in DMD. On the other 
hand, it cannot be excluded that those alterations might be 
a consequence of systemic changes driven by the lack of 
dystrophin, extending far beyond the muscle weakening.
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